← Back to Clinical Trials
Recruiting NCT06819865

NCT06819865 A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06819865
Status Recruiting
Phase
Sponsor Boston Scientific Corporation
Condition Acute Pulmonary Embolism
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2026-08-30
Primary Completion 2027-03-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
EkoSonicTM Endovascular System

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2026-08-30 with a primary completion date of 2027-03-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study to collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.

Eligibility Criteria

Inclusion Criteria: 1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \< 14 days). 2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image 3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient. Exclusion Criteria: 1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \< 14 days). 2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image 3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient.

Contact & Investigator

Central Contact

Guangqi Chang, Doctor

✉ changgq@mail.sysu.edu.cn

📞 020-87755766

Principal Investigator

Cheng Hong, Doctor

PRINCIPAL INVESTIGATOR

The First Affiliated Hospital of Guangzhou Medical University

Frequently Asked Questions

Who can join the NCT06819865 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Pulmonary Embolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06819865 currently recruiting?

Yes, NCT06819865 is actively recruiting participants. Contact the research team at changgq@mail.sysu.edu.cn for enrollment information.

Where is the NCT06819865 trial being conducted?

This trial is being conducted at Guangzhou, China.

Who is sponsoring the NCT06819865 clinical trial?

NCT06819865 is sponsored by Boston Scientific Corporation. The principal investigator is Cheng Hong, Doctor at The First Affiliated Hospital of Guangzhou Medical University. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology